References
- Vella M, Pace D. Glycoconjugate vaccines: an update. Exp Opin Biol Ther 2015; 15(4):529-46; PMID:25496172; http://dx.doi.org/10.1517/14712598.2015.993375
- Safadi MA, Bettinger J, Maturana GM, Enswere G, Borrow R. Evolving meningococcal immunization strategies. Exp Rev Vaccines 2015; 14(4):505-17; PMID:25494168; http://dx.doi.org/10.1586/14760584.2015.979799
- Bröker M, Costantino P, DeTora L, McIntosh ED, Rappuoli R. Biochemical and biological characteristics of Cross-Reacting Material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals 2011; 39:195-204; PMID:21715186; http://dx.doi.org/10.1016/j.biologicals.2011.05.004
- Assay of Diphtheria Vaccine (Adsorbed), General Method 2.7.6. Ph. Eur. 5th Edition, 209-213. Strasbourg. France: Council of Europe, 2004.
- Assay of Tetanus Vaccine (Adsorbed), General Method 2.7.8. Ph. Eur. 5th Edition, 214-217. Strasbourg. France: Council of Europe; 2004.
- Schultz D. Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria. U.S. Patent No. 20,030,099,672. Publication date: 29 May 2003.
- Lockyer K, Gao F, Derrick JP, Bolgiano B. Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines. Vaccine 2015; 33:1345-52; PMID:25640334; http://dx.doi.org/10.1016/j.vaccine.2015.01.046